Skip to content
Search

Latest Stories

Dexcom G6 Sensor may cause adverse skin reactions

The users of Dexcom G6 Sensor, a continuous glucose monitoring system, may experience adverse skin reactions to the sensor, the Medicines and Healthcare products Regulatory Authority (MHRA) has said.

Some users of the Dexcom G6 have experienced adverse skin reactions under the sensor including, redness, swelling and blistering.


The manufacturer, Dexcom, has issued a field safety notice on this identified problem and the use of barrier methods or patches is not recommended as it may affect the performance of the device, the health regulator said in its update to the patients and clinicians including community pharmacists.

“For certain users this is a skin hypersensitivity reaction rather than a simple irritation reaction. Hypersensitivity reactions, also known as allergic reactions, are abnormal reactions involving the immune system to an otherwise harmless chemical,” the MHRA said.

“This reaction may first appear sometime after the first time using the sensor. Once a person has become sensitised to the chemical in the adhesive, the skin will always react to it. Each time they apply the sensor, the reaction may become worse and appear more quickly.”

The use of barrier creams or patches to reduce skin reactions could affect the way the sensor works and therefore the use of barrier creams is not recommended.

The clinicians including community pharmacists have been suggested to identify the patients who have skin reactions, which may include erythema, itching and blistering.

The clinicians are also asked to check whether continued use of the device for patients with skin reactions is suitable. If it is not suitable, then it is suggested to consider the use of alternative glucose monitoring systems for these patients.

“Report skin reactions to the device manufacturer and through your healthcare institution’s local incident reporting system and/or your national incident reporting authority as appropriate,” the health regulator said.

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less